Clinical trials in CNS--SMi's eighth annual conference
- PMID: 20127552
Clinical trials in CNS--SMi's eighth annual conference
Abstract
The SMi's Eighth Annual Conference on Clinical Trials in CNS, held in London, included topics covering new therapeutic developments in the field of CNS disorders. This conference report highlights selected presentations on emerging clinical targets for the treatment of Alzheimer's disease, achievements of the Alzheimer's Disease Neuroimaging Initiative, computational assessment methods applicable to Alzheimer's disease and to the monitoring of suicidality, the accelerated antidepressive effect of PNB-01 (PharmaNeuroBoost NV; comprising a combination of pipamperone and citalopram), and clinical trials in amyotrophic lateral sclerosis and spinal muscular atrophy. Investigational drugs discussed also include begacestat (Pfizer Inc) and olesoxime (Trophos SA).
Similar articles
-
Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.IDrugs. 2009 Dec;12(12):734-7. IDrugs. 2009. PMID: 19943211
-
Society for Neuroscience - 39th Annual Meeting. Part 1 - Novel therapies for the treatment of CNS disorders and pain.IDrugs. 2009 Dec;12(12):731-3. IDrugs. 2009. PMID: 19943210
-
European Neuroscience--Seventh Biennial FENS Forum.IDrugs. 2010 Sep;13(9):607-9. IDrugs. 2010. PMID: 20799140
-
A role for fMRI in optimizing CNS drug development.Nat Rev Drug Discov. 2006 May;5(5):411-24. doi: 10.1038/nrd2027. Nat Rev Drug Discov. 2006. PMID: 16604100 Review.
-
[New drugs in neurology].Praxis (Bern 1994). 1999 Apr 29;88(18):827-34. Praxis (Bern 1994). 1999. PMID: 10409881 Review. German.
Cited by
-
Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis.IDrugs. 2010 Aug;13(8):568-80. IDrugs. 2010. PMID: 20721828 Free PMC article. Review.
-
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease.Nat Rev Neurol. 2019 Feb;15(2):73-88. doi: 10.1038/s41582-018-0116-6. Nat Rev Neurol. 2019. PMID: 30610216 Review.